No price has been set, and Click says its rollout will follow coverage state by state because Medicaid covers a large share of adults with schizophrenia. A first-in-indication clearance reaches only as far as the Medicaid programmes that agree to pay for an app.

• The comparator was active. A digital control makes the 2.6-point gap more credible than a waitlist would, and an effect size of 0.36 is modest but real.
• Click is commercialising alone. Boehringer’s exit from commercial responsibility leaves a digital company building payer access without a pharma partner’s field force.
• The category’s history is the risk. Pear Therapeutics filed for bankruptcy in 2023 after struggling to win reimbursement for its prescription apps, which is why Click is sequencing launch behind coverage.

A 0.61-hour placebo-adjusted OFF-time gain is modest on its own, so the case rests on what comes with it. Discontinuations for adverse events were 3.5% in every arm, including placebo, and dyskinesia ran 4.4% against 1.8%.

• Non-motor signals are the differentiator to test. Epworth sleepiness improved by 0.98 points and PDQ-39 by 2.87 points, both at nominal significance, against a dopaminergic drug class associated with daytime sleepiness.
• The adjunct market just got more crowded. AbbVie’s Juvmo (tavapadon) was approved in late September and Lundbeck began a Phase II of Lu AF28996 this week, so solengepras will be positioned as the option that avoids dopaminergic side effects.
• The filing package is the next disclosure. Cerevance plans to meet FDA on a potential NDA, gave no timing and named no second Phase 3.

Stoke is asking FDA to weigh development alongside seizures, the claim a disease-modifying antisense drug needs to separate itself from anti-seizure medicines. The CEO described FDA as showing willingness to accept the Vineland approach; the release lists no formal agreement.

• On seizures alone the field is crowded. Fenfluramine, stiripentol and cannabidiol are approved in Dravet syndrome, so a label limited to seizure frequency would put zorevunersen among several options.
• Data go in before the readout. Stoke plans to submit data throughout the first half of 2027, which shortens the gap between topline and a complete filing.
• The designations stack up. Breakthrough Therapy in the US and China, orphan status in the US and EU, and Rare Pediatric Disease designation.

The price is for the labels still to come. Shionogi is buying a molecule that keeps collecting rare neurology labels, and it bolts onto the rare disease unit Shionogi built around Radicava, bought from Tanabe Pharma for $2.5 billion in April.

• The A-T label is weeks old. It rested on a 73-patient crossover study, as covered in NeuroPulse Week 38.
• CACNA1A is the next test. IB1001-304 was due to complete enrolment in October, in disorders Fierce Pharma puts at about 30,000 US patients.
• NPC is filling up. Two drugs are approved, and Rafael plans an NDA for Trappsol Cyclo after missing its pivotal primary, as covered in Week 40. The deal terms are in DealPulse Signal Week 41.

The target is the patient heading for a pump or a device. Lundbeck positions Lu AF28996 for people who would otherwise rely on invasive or continuous-delivery therapies, an oral option at the advanced stage.

• Open-label numbers flatter. The changes are from baseline with no control arm, and Lundbeck calls them descriptive. DARE2 is the first controlled test.
• Dyskinesia moved the right way. Troublesome dyskinesia fell by 1.2 hours at Week 6 and UDysRS by 14.5 points at Week 18, from a baseline of 28.3, which DARE2 needs to confirm against placebo.
• Three mechanisms arrived within a fortnight. Tavapadon’s D1/D5 partial agonism, solengepras’s non-dopaminergic GPR6 route and Lundbeck’s D1/D2 prodrug all reported between late September and 7 October.

$100 million compares with $138.7 million of cash at the end of September, according to Fierce Biotech, and moves Alector’s runway guidance from at least through 2027 to into 2029. Alector licensed one molecule and kept the delivery platform that made it valuable.

• The biology is GBA-linked Parkinson’s. GCase deficiency, tied to GBA mutations and alpha-synuclein build-up, is what the enzyme is designed to correct.
• The clinic is undated. Alector dropped its 2027 target for first human testing in May.
• Spur shares the upside. Spur Therapeutics receives a percentage in the teens of sublicensing milestones under the engineered GCase patent option, which Alector exercised by committing $15 million.

Progranulin is the target-engagement number every FTD-GRN programme is judged on, and AVB-101 shows a dose response. The neurofilament reading matters more: natural history suggests NfL rises by at least 13% to 14% a year, so a flat line in treated patients is an early sign of slowed neurodegeneration if it holds at higher doses.

• Delivery is the differentiator. A one-time thalamic infusion aims for broad cortical reach from a deep relay, against the intracisternal routes used by other programmes.
• Neurosurgery sets the ceiling on scale. AviadoBio is standardising the procedure across five expert neurosurgical centres.
• Higher-dose NfL is the next read. Long-term neurofilament data from cohorts three and four are pending.

Autologous means one manufacturing run per patient, the trade Aspen makes against donor-derived cell lines: cells matched to the patient, against harder cost and scale.

• The IPO is the financing test. A $100 million raise against a 2027 Phase 3 start shows how far public markets will fund regenerative neurology before controlled efficacy data.
• RMAT is the regulatory lever. The designation opens discussion of accelerated approval on surrogate or intermediate endpoints, which matters for a single-dose therapy.
• Watch the prospectus for durability. Fifteen dosed patients is the dataset investors will price, and how long the earliest have been followed is the number that matters.

Generic tablets bring the first price competition to perampanel. Catalyst Pharmaceuticals, which acquired Fycompa’s US rights from Eisai in 2023, holds the reference product.

• Tablets only. The approval covers six tablet strengths; the report does not mention the oral suspension used in younger children.
• Launch timing sets the curve. Aurobindo’s third fiscal quarter runs to the end of December, which puts a launch late in calendar 2026.
• Aurobindo now holds 599 ANDA approvals, 574 final and 25 tentative, so perampanel is one launch in a deep generic pipeline.

Prescription records show the overlap; they cannot show whether anyone was warned. The right contraceptive exists for most people on these drugs, which is why the authors frame the fix as counselling.

• Not every combination interacts. Some contraceptive methods and some anti-seizure medicines are unaffected, so the fix is a prescribing choice that already exists.
• It falls between two prescribers. Contraception is usually prescribed outside epilepsy care, so the interaction sits between the neurologist and whoever writes the contraceptive.
• Outcomes are the missing piece. The study did not examine pregnancies or contraceptive failure, and prescription data cannot confirm what patients took.